Eplerenone , a Selective Aldosterone Blocker , in Patients with Left Ventricular Dysfunction after Myocardial Infarction

B. Pitt,W. Remme,F. Zannad,J. Neaton,F. Martinez,B. Roniker,R. Bittman,Steve Hurley,J. Kleiman,M. Gatlin

Published 2003 in Unknown venue

ABSTRACT

No abstract is available for this paper.

PUBLICATION RECORD

Publication year
2003
Venue
Unknown venue
Publication date
Unknown publication date
Fields of study
Not labeled
Identifiers
No identifiers available.
External record
Open on Semantic Scholar
Source metadata
Semantic Scholar

CITATION MAP

EXTRACTION MAP

CLAIMS

No claims are published for this paper.

CONCEPTS

No concepts are published for this paper.

REFERENCES

The EPHESUS Trial: Eplerenone in Patients with Heart Failure Due to Systolic Dysfunction Complicating Acute Myocardial Infarction
2004cited by this paper
Aldosterone-induced inflammation in the rat heart : role of oxidative stress.
2002cited by this paper
The renin-angiotensin-aldosterone system excites hypothalamic paraventricular nucleus neurons in heart failure.
2002cited by this paper
Aldosterone induces a vascular inflammatory phenotype in the rat heart.
2002cited by this paper
Prevalence and Incidence of Arrhythmias and Sudden Death in Heart Failure
2002cited by this paper
Effects of Long-Term Monotherapy With Eplerenone, a Novel Aldosterone Blocker, on Progression of Left Ventricular Dysfunction and Remodeling in Dogs With Heart Failure
2002cited by this paper
Addition of spironolactone to angiotensin-converting enzyme inhibition in heart failure improves endothelial vasomotor dysfunction: role of vascular superoxide anion formation and endothelial nitric oxide synthase expression.
2002cited by this paper
Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart.
2002cited by this paper
Mineralocorticoid Receptor Antagonism in Experimental Atherosclerosis
2002cited by this paper
Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan.
2002cited by this paper
Effect of a selective aldosterone receptor antagonist in myocardial infarction.
2001cited by this paper
Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial.
2001cited by this paper
Calculating the number needed to treat for trials where the outcome is time to an event
1999cited by this paper
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
1999cited by this paper
Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients.
1997cited by this paper
Mechanisms Determining Course and Outcome of Diabetic Patients Who Have Had Acute Myocardial Infarction
1997cited by this paper
Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease.
1995cited by this paper
Sample size calculation for complex clinical trials with survival endpoints.
1995cited by this paper
Chronic administration of aldosterone depresses baroreceptor reflex function in the dog.
1994cited by this paper
Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro.
1987cited by this paper
Prediction of creatinine clearance from serum creatinine.
1975cited by this paper

CITED BY

Spectrum of Primary Aldosteronism and Risk of Cardiovascular Outcomes: The Atherosclerosis Risk in Communities Study.
2026cites this paper
Chemical profiling and multi-dimensional pharmacokinetic analysis of shengmaiyin oral liquid for cardiac dysfunction.
2026cites this paper
Cardio-Renal Syndrome: Review and New Perspectives
2026cites this paper
The Mechanism of Action of Mineralocorticoid Receptor Antagonists in Heart Failure with Reduced Ejection Fraction
2026cites this paper
Evolving Mineralocorticoid Receptor Antagonism: a Narrative Review on Differences between Steroidal MRAs, Non-Steroidal MRAs and Aldosterone Synthase Inhibitors in Cardiorenal Disease
2026influential citation
New drug therapies for hypertension.
2026cites this paper
Future Directions and Innovations in Mineralocorticoid Receptor Antagonist Therapy
2026cites this paper
Bradycardia, Hyperkalemia, Renal Dysfunction, and Hypoglycemia in Guideline-Directed Medical Therapy for Heart Failure: When to Tolerate and When to Worry.
2026cites this paper
The Role of Aldosterone in Vascular Permeability in Diabetes
2026cites this paper
The Pharmacological Properties and Safety Profile of Mineralocorticoid Receptor Antagonists in Heart Failure with Reduced Ejection Fraction
2026cites this paper
Safety and efficacy of early initiation of mineralocorticoid receptor antagonist after an acute decompensated heart failure event or acute myocardial infarction with cardiac dysfunction: a meta-analysis of randomized clinical trials.
2026cites this paper
The Intersection of Heart Failure and Chronic Kidney Disease: Challenges in Co-management
2026cites this paper
Real-world Utilization of Mineralocorticoid Receptor Antagonists in India and the Benefits of GDMT in Heart Failure
2026cites this paper
Mineralocorticoid Receptor Antagonists: The Pillar Drug in Heart Failure
2026cites this paper
Plasma Aldosterone Measurement to Guide Prevention and Treatment of Heart Failure in Black Adults With Hypertension.
2026cites this paper
Early Initiation and Dose Optimization of Mineralocorticoid Receptor Antagonists in Heart Failure
2026cites this paper
Kidney Protection Options in 2025: Are Renin-Angiotensin System Inhibitors Still Needed?
2026cites this paper
Tackling Therapeutic Inertia on Mineralocorticoid Receptor Antagonist Adoption in Heart Failure
2026cites this paper
The mineralocorticoid receptor: a new chapter for therapeutic regulation of diabetic cardiomyopathy.
2026cites this paper
The Role of Mineralocorticoid Receptors in the Treatment of Primary Hypertension
2026cites this paper
Targeting Diabetic Atherosclerosis: The Role of GLP-1 Receptor Agonists, SGLT2 Inhibitors, and Nonsteroidal Mineralocorticoid Receptor Antagonists in Vascular Protection and Disease Modulation
2025cites this paper
Coronary Artery Disease and Heart Failure: Medical Management and Future Direction.
2025cites this paper
Left Ventricular Remodeling After Myocardial Infarction—Pathophysiology, Diagnostic Approach and Management During Cardiac Rehabilitation
2025cites this paper
Protocolo de prevención primaria y secundaria de la cardiopatía isquémica
2025cites this paper
EVATRAN (The Effect of Eplerenone on the Evolution of Vasculopathy in Renal Transplant Patients): study protocol for a cross-over randomized controlled trial
2025cites this paper
Impact of Finerenone in Patients with Heart Failure and Reduced/Mildly Reduced Ejection Fraction, Diabetes Mellitus, and Chronic Kidney Disease
2025cites this paper
Treatment Patterns, Adverse Events, and Clinical Outcomes with Steroidal Mineralocorticoid Receptor Antagonists: A Retrospective Analysis of Administrative Claims Data (RELICS)
2025cites this paper
Linking Cardiovascular Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): The Role of Cardiometabolic Drugs in MASLD Treatment
2025cites this paper
Mineralocorticoid Receptor Antagonism with Finerenone: A New Era in the Management of Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction
2025cites this paper
In Silico Investigation of Mineralocorticoid Receptor Antagonists: Insights into Binding Mechanisms and Structural Dynamics
2025cites this paper
The Continuum of Prevention and Heart Failure in Cardiovascular Medicine: A Joint Scientific Statement from the Heart Failure Society of America and The American Society for Preventive Cardiology.
2025cites this paper
Targeting Heart Disease in Cardiovascular–Kidney–Metabolic Syndrome: A Review of Novel Therapeutic Approaches with Prognostic and Quality-of-Life Impact
2025cites this paper
Evaluation of Optimization of Drug Therapy in Heart Failure Patients with reduced ejection Fraction in the Outpatient Department and Emergency Department of a Central Hospital
2025cites this paper
Comparative Efficacy and Safety of Finerenone, Eplerenone, and Spironolactone on Cardiorenal Outcomes in Type 2 Diabetes with Chronic Kidney Disease: A Systematic Review and Network Meta-Analysis
2025cites this paper
What to do with key cardiovascular drugs when kidney function worsens?
2025cites this paper
Mineralocorticoid receptor antagonism of vamorolone: Evidence from LIONHEART and VISION-DMD clinical trials.
2025cites this paper
Fostering interconnected care in heart failure: a call to action for a comprehensive assessment and management of the patient’s journey
2025cites this paper
Finerenone in diabetic chronic kidney disease—Real‐world insights including patients with HFpEF or HFmrEF
2025cites this paper
Cardiovascular-Kidney-Metabolic Effects: Steroidal and Nonsteroidal Mineralocorticoid Receptor Antagonists
2025influential citation
Optimizing the Primary Prevention of Sudden Cardiac Death in Patients With Heart Failure.
2025cites this paper
Trends and disparities in heart failure mortality with and without chronic kidney disease in a nationwide retrospective analysis
2025cites this paper
Pharmacology and Therapeutic Potential of Finerenone: A Novel Third-Generation Nonsteroidal Mineralocorticoid Receptor Antagonist
2025influential citation
Overcoming Clinical Inertia in the Context of Non-Adherence With Guideline-Directed Medical Therapy for Heart Failure
2025cites this paper
Nonsteroidal and Steroidal Mineralocorticoid Antagonists: Rationale, Evidence, and Unanswered Questions.
2025cites this paper
Benefit–risk of colchicine and spironolactone in acute myocardial infarction: a prespecified generalised pairwise comparisons analysis of the CLEAR trial
2025cites this paper
Aldosterone: From Essential Tubular Regulator to Pathological Driver—Physiology, Disease, and Therapeutic Advances
2025cites this paper
Efficacy and safety of mineralocorticoid receptor antagonists in heart failure: a meta-analysis of randomized controlled trials
2025cites this paper
Real-world use of finerenone in diabetic kidney disease: eGFR slope analysis with exploratory data on prior MRA use
2025cites this paper
Antihypertensive therapy to prevent cardiac death: A study of combined ACE inhibitors and β-blockers—a retrospective cohort study in Tsunan Town, Japan
2025cites this paper
The Moreton Lecture Series: The Renin-Angiotensin-Aldosterone System-Physiology, Pathophysiology, and Pharmacological Inhibition.
2025cites this paper
Weekly Journal Scan: A CLEAR message questions the routine use of spironolactone in acute myocardial infarction.
2025cites this paper
Revisiting renin-angiotensin-aldosterone system in aging: translational insights from bench to bedside and back
2025cites this paper
Guideline‐directed medical therapy rates in heart failure patients with reduced ejection fraction in a diverse cohort
2025cites this paper
The endothelial surface layer-glycocalyx - Universal nano-infrastructure is fundamental to physiology, cell traffic and a complementary neural network.
2025cites this paper
CLEAR SYNERGY: Can routine spironolactone improve post-MI outcomes?
2025cites this paper
Therapeutic Appraisal in Protracted Heart Failure.
2025cites this paper
Mineralocorticoid receptor antagonism for non-diabetic kidney disease
2025cites this paper
Impact of sodium‒glucose cotransporter‐2 inhibitors in patients with recent versus previous myocardial infarction: a systematic review and meta-analysis
2025cites this paper
2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.
2025cites this paper
Medical therapy and outcomes in REVIVED-BCIS2 and STICHES: an individual patient data analysis
2025cites this paper
Inflammation in atherosclerotic cardiovascular disease: From diagnosis to treatment
2025cites this paper
Assessing the application of American Heart Association (AHA) guidelines in the management of heart failure with reduced ejection fraction
2025cites this paper
Interaction Between Aldosterone and Mineralocorticoid Receptor Antagonist: Findings From the EPHESUS Trial.
2025cites this paper
Current Application of Mineralocorticoid Antagonist (MRA) in Heart Failure and CKD: Does Non-Steroidal Drug Add Novel Insights
2025cites this paper
The continuum of prevention and heart failure in cardiovascular medicine: A joint scientific statement from the Heart Failure Society of America and the American Society for Preventive Cardiology
2025cites this paper
Dose optimization and utilization trends of mineralocorticoid receptor antagonists in heart failure patients with reduced ejection fraction in Ethiopia
2025cites this paper
Exploring the Mechanism of Action of Berberine on Arrhythmia After Myocardial Infarction: A Network Pharmacology, Molecular Docking, and Cellular Experimental Study
2025cites this paper
Supersaturated oxygen therapy using radial artery access to prevent left ventricular remodeling after anterior ST-segment elevation myocardial infarction: a randomized, controlled trial
2025cites this paper
The Aldosterone Blockade for Health Improvement Evaluation in End-Stage Renal Disease (ACHIEVE) Trial: Rationale and Clinical Research Protocol
2025cites this paper
Mineralocorticoid receptor phase separation modulates cardiac preservation
2025cites this paper
Device-based Strategies for Monitoring Congestion and Guideline-directed Therapy in Heart Failure: The Who, When and How of Personalised Care
2025cites this paper
Mineralocorticoid receptor antagonists in heart failure: Comparative Insights on Spironolactone and Finerenone across the Ejection Fraction Spectrum
2025cites this paper
Use of finerenone in patients with chronic kidney disease at high risk of heart failure.
2025cites this paper
The role of aldosterone on the endothelial dysfunction induced by female hormone deficiency.
2025cites this paper
Implication of the Dose of Mineralocorticoid Receptor Antagonist Following Transcatheter Edge-to-Edge Mitral Valve Repair
2025cites this paper
Postpartum administration of eplerenone to mitigate vascular dysfunction in mice following a preeclampsia-like pregnancy
2025cites this paper
The role of finerenone in the concomitant management of chronic kidney disease-type 2 diabetes and the implication for heart failure prevention and treatment
2025cites this paper
Readmission Rates in Reduced Ejection Fraction Heart Failure Patients on Triple Guideline-Directed Medical Therapy at Hospital Discharge
2025cites this paper
Escaping Injury From Elevated Aldosterone: More Data in Support of MR Antagonism.
2025cites this paper
Cardiovascular-Kidney-Metabolic Health: Definition, Staging, Risk Assessment, and Therapeutic Considerations.
2025cites this paper
Mineralocorticoid Receptor Antagonists in Myocardial Infarction Patients: A Systematic Review and Meta-Analysis of Randomized Trials.
2025cites this paper
To MRAs treatment or not? evidence from a meta-analysis of randomized controlled trials of different MRAs on cardiovascular health in heart failure
2025cites this paper
Eplerenone alleviates diabetic cardiomyopathy by modulating ER stress, oxidative stress, and NLRP3 inflammasome activation
2025cites this paper
Interplay Between the Mineralocorticoid System, Inflammation, Hypertension, and Kidney Disease
2025cites this paper
Aldosterone and Aldosterone Modulation in Cardio-Kidney Diseases.
2025cites this paper
Kidney function trajectories before and after hospitalization for heart failure with reduced ejection fraction
2025cites this paper
The Emerging Role of Aldosterone Synthase Inhibitors in Overcoming Renin–Angiotensin–Aldosterone System Therapy Limitations: A Narrative Review
2025cites this paper
Heart Failure Readmission Prevention Strategies—A Comparative Review of Medications, Devices, and Other Interventions
2025cites this paper
Evidentiary Landscape of Heart Failure Therapies, Regulatory Decisions, and Translation Into Guidelines.
2025cites this paper
Hipertensión arterial mineralocorticoidea
2025cites this paper
Prevention of heart failure after acute myocardial infarction.
2025cites this paper
Mineralocorticoid receptor antagonists in heart failure: a systematic review and meta-analysis
2025cites this paper
Drug treatment of chronic heart failure with reduced ejection fraction
2025cites this paper
Review of Current Management of Myocardial Infarction
2025cites this paper
Sodium zirconium cyclosilicate for MRAs optimization in HFrEF: lessons learned from the REALIZE-K trial
2025cites this paper
Benefits of aldosterone receptor antagonism in chronic kidney disease: the BARACK-D RCT.
2025cites this paper
Wirkt die moderne pharmakologische Herzinsuffizienztherapie antiarrhythmisch?
2025cites this paper
Cardiovascular Benefits of Spironolactone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction: Insights from a Win Ratio Analysis of the TOPCAT Trial
2025cites this paper
When Kidney Function Declines But Therapy Still Works: The Case for Nonsteroidal MRA Therapy in Heart Failure.
2025cites this paper
Investigating the efficacy of mineralocorticoid receptor antagonists for cardiovascular outcomes in different diseases
2025cites this paper